Please try another search
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline products include ACD856, which is in phase I clinical trial to treat Alzheimer’s disease, sleep disorders, traumatic brain injuries, and Parkinson’s disease; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Thomas Pollare | 70 | 2017 | Chairman |
Ragnar Linder | 70 | 2017 | Independent Director |
Sven Ove Ogren | - | - | Scientific Advisor |
Henrik Zetterberg | - | - | Scientific Advisor |
Eva Lilienberg | 67 | 2021 | Independent Director |
Ellen K. Donnelly | 49 | 2018 | Independent Director |
Peter Jeffrey Snyder | - | - | Scientific Advisor |
Bengt Winblad | - | - | Scientific Advisor |
Rolf Karlsten | - | - | Scientific Advisor |
John Harrison | - | - | Scientific Advisor |
Janet Hoogstraate | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review